Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in

ASH 2024

2024 ASH Annual Meeting

7–10 December 2024 | San Diego

The 66th ASH Annual Meeting and Exposition was a key event for hematology experts from across the world to discover cutting-edge research and get access to the latest advances in the field. We bring you official videos and breaking news from the conference.

inMIND supports tafasitamab addition to R/R follicular lymphoma regimen

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring official congress content from ASH

Transplantation can be omitted for certain MCL patients

Use of autologous transplantation does not improve the survival of people with mantle cell lymphoma and undetectable minimal residual disease after induction therapy.

Featuring official congress content from ASH

Oncology Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy oncologist.

Subscribe now

AQUILA supports active therapy for smoldering multiple myeloma

Treatment with daratumumab reduces the likelihood of smoldering multiple myeloma progressing to active disease compared with active monitoring.

Promising response to loncastuximab tesirine in lymphoma

The antibody–drug conjugate loncastuximab tesirine has shown encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma.

Add-on blinatumomab improves DFS in children with ALL

Phase 3 trial findings support the use of blinatumomab alongside first-line chemotherapy for childhood standard-risk, B-cell acute lymphoblastic leukemia.

Smoking intensity, genetic mutations, and disease progression in MDS

Smoking may be associated with several genetic mutations related to myelodysplastic syndrome, suggesting that it may contribute to molecular pathogenesis.

Conference highlights

Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies

A session focusing on the emerging research investigating the host–gut microbiome axis in the context of response to stem cell transplantation and CAR T-cell therapy. Watch the presentations by Prof. Florent Malard, Dr. Lawrence David, and Dr. Tessa Andermann, and the audience Q&A.

Featuring official congress content from ASH

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Dr. Laurie Sehn presents the findings of the inMIND trial showing the benefit of combining two monoclonal antibodies for the treatment of relapsed or refractory follicular lymphoma.

Featuring official congress content from ASH

Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission with Undetectable Minimal Residual Disease: Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Dr. Timothy  Fenske reports phase 3 data demonstrating that autologous hematopoietic cell transplantation can be omitted for certain patients with mantle cell lymphoma.

Featuring official congress content from ASH

AI quantification of sickle cell morphology as an objective disease marker of SCD

An AI-guided approach in the analysis of imaging flow cytometry data may help predict the severity of sickle cell disease.

Screening for iron deficiency in women is cost-effective

Screening and treating women with iron deficiency before progression to iron deficiency anemia is a cost-effective approach.

First-line treatment with eltrombopag in children with newly diagnosed ITP

Treatment with eltrombopag results in a significantly higher platelet response than current therapies in children with newly diagnosed immune thrombocytopenia.

Benefit of pirtobrutinib in pretreated patients with CLL/SLL

In pretreated patients with CLL/SLL, treatment with pirtobrutinib resulted in a significant improvement in PFS compared with idelalisib plus rituximab or bendamustine plus rituximab.

AMPLIFY supports BTK inhibitor combination for CLL

AMPLIFY trial findings indicate that first-line acalabrutinib plus venetoclax with or without obinutuzumab may improve progression-free survival in chronic lymphocytic leukemia.

Read more

Persistently better PFS with zanubrutinib in untreated CLL

Patients with previously untreated chronic lymphocytic leukemia without del(17p) treated with zanubrutinib have a sustained PFS benefit over patients treated with bendamustine in combination with rituximab.

Rilzabrutinib safe and effective in ITP

The BTK inhibitor rilzabrutinib has demonstrated a strong therapeutic effect and favorable safety profile in patients with immune thrombocytopenia.

Cell-free DNA predicts DLBCL treatment outcomes

Cell-free DNA shows promise as a biomarker for predicting clinical outcomes in patients with diffuse large B-cell lymphoma.

More fiber results in better OS and less GVHD in allo-HCT

Higher fiber intake after allogeneic hematopoietic stem cell transplantation appears to be associated with better overall survival and lower incidence of lower gastrointestinal GVHD.

Bicistronic CD19/CD22 CAR T-cell therapy in children with B-ALL

Bicistronic CD19/CD22-targeted CAR T-cell therapy appears to be a safe and effective regimen that results in durable remission in children with relapsing or refractory B-cell acute lymphoblastic leukemia.

Stay up to date with more from Springer Medicine

Case-based insights: Oncology and hematology

Refresh your knowledge in Oncology and Hematology

  • 45 clinical cases across different topics with relevant clinical images
  • Written by renowned experts 
  • Knowledge-check questions with answers

Episode 9: The gut microbiome and CAR T-cell therapy

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe
Developed by: Springer Medicine

Symposium (Link opens in a new window)

An independent symposium at the 10th COMy World Congress focusing on BCMA-targeting strategies for the treatment of multiple myeloma. Gain insights into the latest clinical data and the implications for clinical practice.

Supported by:
  • GlaxoSmithKline
Developed by: Springer Healthcare IME
Image Credits